ARGOMENTO: BOOKS > BIOLOGIA > BIOLOGIA > CHIMICA E BIOCHIMICA

mRNA Vaccines

Name: mRNA Vaccines
Price: 144,38 € EUR
Availability: InStock
Author: Yu Dong (Curatore); Petsch Benjamin (Curatore)
ISBN: 9783031180699

yu dong (curatore); petsch benjamin (curatore)

Disponibilità: Normalmente disponibile in 15 giorni

PREZZO
151,98 €

NICEPRICE
144,38 €

SCONTO
5%

Acquista

Questo prodotto usufruisce delle SPEDIZIONI GRATIS
selezionando l'opzione Corriere Veloce in fase di ordine.

Pagabile anche con 18App Bonus Cultura e Carta del Docente

Dettagli

Genere:Libro

Lingua: Inglese

Editore:

Springer

Pubblicazione: 01/2023

Edizione: 1st ed. 2022

Trama

The formulation and the technological advancements in RNA biology, chemistry, stability, and encapsulated delivery systems that have enabled the development of fully synthetic mRNA vaccines are discussed in this volume. The applications of the mRNA technology is covered, focusing on infectious diseases but also touching on other indications, such as immunotherapies and molecular therapies. Potent and long-lasting immune responses observed in animal models, encouraging data from early human clinical studies, together with the success of two mRNA-based COVID-19 vaccines support the use of mRNA-based vaccination as an attractive alternative to conventional vaccine approaches. Consequently, the development progress of the technology, particularly on production, capabilities, and clinical development is reviewed. Topics on safety, regulatory issues, and possible challenges to the mRNA vaccination approach round off this book. Thanks to their high potency, the prospect for generic, low-cost manufacturing processes, and entirely synthetic nature, the future for mRNA vaccines is highly promising. Importantly, mRNA vaccines have the potential to minimize the time between pathogen identification and vaccine release with a huge impact on public health.

As the mRNA-based vaccination technology has been progressing rapidly, the book is intended to be an end-to-end review series, covering everything from basic RNA biology and preclinical studies to the manufacturing strategy, clinical development and regulatory approval. It provides established RNA researchers and developers with updates on the latest advancements in the field and allows for a quick but comprehensive overview of this transformative technology, its application, and future potential.

Sommario

Foreword - RNA technology overview

Dong Yu (dong.x.yu@gsk.com) (GSK) & Frank Bähner (Frank.Baehner@curevac.com) (CureVac) – confirmed

Conventional mRNA-based technology & mode of action

Benjamin Petsch (benjamin.petsch@curevac.com) (CureVac) – confirmed

Self-amplifying RNA-based technology & mode of action

Jeffrey Ulmer (jeffrey.b.ulmer@gsk.com)/Dong Yu (dong.x.yu@gsk.com) (GSK) – confirmed

Delivery and formulation technologies

Yizhou Dong (dong.525@osu.edu) (Ohio State) – confirmed

RNA for infectious disease applications

Drew Weissman (dreww@pennmedicine.upenn.edu) (U Penn) – confirmed

RNA for other indications (immunotherapies/oncology, molecular therapies - a potential topic)

Tim Wagenaar (Timothy.Wagenaar@sanofi.com) (Sanofi) – tentatively confirmed, likely working with Biotech; Backup - Katalin Karikó (BioNTech)

Production and capabilities

Heinrich Haas (Heinrich.Haas@biontech.de) (Biontech) – waiting for response; Backup - Juan Andres (Moderna)

Clinical development

Tal Zaks (Tal.Zaks@modernatx.com) (Moderna) – tentatively confirmed; Backup - Anna Collén (AstraZeneca)

Other considerations (e.g., safety, regulatory issues, challenges)

Mark Tracy (mark@tracybioconsulting.com) (Tracy Bioconsulting) – waiting for response

Autore

Dr. Dong Yu currently is Senior Vice President of Research at Dynavax Technologies. Prior to joining Dynavax, Dr. Yu was the Head of Preclinical R&D US at GSK Vaccines. He received the PhD from University of Connecticut Health Center. He was a faculty member at Washington University in Saint Louis and the Head of Microbial Molecular Biology at Novartis Vaccines prior to joining GSK Vaccines in 2015. Dr. Yu authored over 40 publications in various journals and books. His publications reflect his research interests in virology, infectious diseases, and vaccines.

Dr. Benjamin Petsch, Senior Director Prophylactic Vaccine Research at CureVac AG, Benjamin Petsch joined CureVac in 2010 as a scientist in the vaccines department developing mRNA based vaccines against infectious diseases and is heading the department since 2013. He received his university degree from Ludwig-Maximilians-University of Munich and performed his doctoral thesis at the Friedrich-Loeffler-Institut, Tübingen, where he continued as a postdoc and research group leader working on mRNA vaccination against Influenza and on intervention of Influenza replication using small molecules. Dr. Petsch has a 10+ years scientific experience on mRNA based prophylactic vaccines.